FAX



Type site code here

To Examiner Richard Raymond, Group Art U: 1624 Company USPTO Fax 571 273-0673 From Lorie Ann Morgan Tel / Fax 919 483-8222 / 919 483-7977 Lorie.A.Morgan@gsk.com E-mail Date 21-Oct-2004 Pages including cover 6

Serial No. 10/089,964 Filing Date: 8 May 2002 Applicant: Alvaro et al. Title: Chemical Compounds

Subject USSN 10/089,964

Attached: Copy of IDS and PTO-1449 filed 18 May 2004 and confirmation of receipt by PTO.

Dear Ex. Raymond,

Attached for your consideration is a copy of the IDS and PTO-1449 filed 18 May 2004 together with confirmation of receipt by the PTO. Kindly consider the reference identified on the PTO-1449 in connection with the above-referenced patent application and return an initialed copy of the PTO-1449 at your earliest convenience. I would be grateful to receive the initialed PTO-1449 before the due date for filing the issue fee.

Applicants also respectfully request favorable consideration of the Petition to Change Inventorship, filed on 15 June 2004,

Thank you for your assistance in this case and please do not hesitate to contact me should you require anything further.

Sincerely,


Lorie Ann Morgan Reg. No. 38,181 Attorney for Applicants

GlaxoSmithKline phone: 919 483-8222

919 483-7977 fax:

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

FAX



gsk GlaxoSmithKline

Glaxo Wellcome Inc. PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com

Serial No.: 10/089,964
Filing Date: May 8, 2002
Applicant: Alvaro et al.
Title: Chemical Compounds

Attached: Transmittal Form w/Certificate of transmission via facsimilie Supplemental IDS PTO1449 1 Reference

Thank you, Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on May 18, 2004.

Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PI3806USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alvaro et al.

Serial No.:

10/089,964

Group Art Unit: 1624

File Date:

May 8, 2002

Examiner:

R. Raymond

For:

Chemical Compounds

Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandría, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] C [] A su at	opies of the references are enclosed: opies of the references were submitted in parent application Scrial No (37 CFR 1.98(d)) copy of the International Scarch Report which issued on International Application No is bmitted herewith. All of the publications cited in the International Search Report are listed on the tached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent ffice by the International Bureau.
A.	£1	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last 37 CFR 1.97(b).
	OR [)	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
B.	[X]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the morits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(e) (\$180.00).
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

PI3806USW

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The position fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan

Registration No. 38,181

Date: 5/18/04 GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

Auto-Reply Facsimile Transmission



TO:

Fax Sender at 919 483 5730

Fax Information Date Received: Total Pages:

5/18/2004 10:21:55 AM [Eastern Daylight Time]

18 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received Cover Page

=====>

	WAT 9.5004 10:595H GN 910381 243 15	NO. 8268 7 1
	BANK IN SOCIA 10-CAND ON APPARE AND AP	1
		GlazoSmlthKline
	FAX	
-	To Aim: Group Art Unit 1524	Clické William int. PC Box 1984
	Company USPTO	Piero (Apure Debis America) Transport and Math Carreles 22705
	Fext 709-872-9306	Tel: \$11.453.2100
	Fenan Valore L. Philips	
	T-4 019-443-8273 FAX 918-488-5780	
	E-mail Y047157(Book com	
	Administration of the second s	
[Subject Supplemental DR	•
ŀ	Serial Na.: 10/059,864 Filing Date: May B. 2002	
	Applicant: Alvan et al. Tita: Chemical Compounds	
١-		
 .	Attached Transmittel Form w/Centificate of transmission via fessimile	
1	Supplemental TDS PTO 1448 1 Reference	
	Trank you.	
Ī	Valerie Philips	
Į.		
ì		
ļ	Continues of Temperaturing by Facelinth (87 CFR 1.8)	
ŀ	I hearthy certify that this Supplemental EDS is being lacateries or handtad Trademiers Cellos (Fan. 242, 703-872-9306) on May 16, 2004.	I to the United Status Pattent BIN
1	Minux Million	
1	Veleric L. Philips	
-		•
		and in Irlandard for the earlier his raid () Sie
	The automation contained in these decayments is considered along may also an investigate noticesses among taken and to be not only to the inheritant recipient or the amplicate to the noticesses among taken and to be not produced to the new or below the control of the control of the second of the control	ori (ethornalis is do lem il to the bymestes. his communication in micity prahárhad. If you
	The advantage presents in 1904 and the Pool and the Proplet of the Confedence of the	<u>vel ya cih alama ka ka kacum.</u>
	18 * REVO AT 5/182004 (DE21:55 AM Elaston Doublet Time! SVII US PTO-EFREF-IR! DRS. REZUMA: CRE	N-649 FPS C796 NTHREE TIME home and \$7.85
 PAGE 1/1 	JR. M. AD VI STRAIN JACKSON BENZEN (VARAN FINC). SANGES (A. 170, 170, 170, 170, 170, 170, 170, 170,	1-213 deli At At Antiditare hausvirus At

Page 1 of 1

FORM PTO-1 INFORMATION	449 ON DISCLOSURE ST	ratement	PI3806USW	ATTORNEY DOCKET NO. PI3806USW APPLICANT: Alvaro et al.		SERIAL NO. 10/089,964	
				VEI O EC AL.			
			FILING DATE: May 8, 2002	1	GROUP 1624		
		IIS P	ATENT DOCUMENTS		.^~		
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
RR	5,576,317	Nov. 19, 1996	Gonsalves et al.	514	231.2		
-/ \ \ -							
					<u> </u>	 	
						 	
						 	
					ļ	 	
					 	+	
					 	 	
		<u> </u>	<u> </u>		<u></u>	٠	
		Co	ntinuc on page N PATENT DOCUMENTS				
			PATENT DOCUMENTS		1	Translation	
	Document	Publication Date	Country	Class	Subclass	Yes No	
	Number	- Date	- Country			 	
		 					
							
		1					
						<u> </u>	
						 	
			· · · · · · ·				
		Co	ontinue on page	4 30 37	F4- \		
	OTHER DOCU	MENTS (Includia	g Author, Title, Journal-Da	ite, Page Numo	er, etc.)		
				<u> </u>			
		· · · · · · · · · · · · · · · · · · ·					
		<u></u>	<u>, </u>				
							
			<u></u> .				
							
	\sim		ontinue on page	DATE	ONGIDERED		
EXAMINER	Ma	ymy/			ONSIDERED	L.	
EXAMINER:	Initial if citation consi- mance and not consider	dered, whether or n red. Include copy	of this form with next commu	with MPEP § 60 nication to the a	pplicant.	TOUGH CHARLOT	